To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Recruiting · NCT06578676 · Interventional (participants receive a specific treatment) · Lead sponsor: Hyundai Pharm
View the official record on ClinicalTrials.gov →Interventions studied
Empagliflozin 25 MGEmpagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mgEzetimibe/Rosuvastatin 10/10mg
What this trial is about
The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Signed informed consent
- Age: 19 and over , healthy volunteer
- Body mass index (BMI): 18.5≤BMI≤29.9 kg/m²
Exclusion criteria
- Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination or effects of the study drugs will not be normal
- Clinically relevant findings(e.g. blood pressure, electrocardiogram(ECG); physical and gynecological examination, laboratory examination)
Where it is running
1 location listed.
- Kyungpook national university hospital - Daegu, Gyeongsangbuk-do, South Korea